Drugs and biologics: the IND (21 CFR Part 312)
- Pre-IND meeting: optional but recommended, to discuss design and regulatory strategy before you submit. 21 CFR 312.82(a) provides for it for drugs treating life-threatening and severely debilitating illnesses; other sponsors use FDA’s formal meetings process.
- Submission: protocol, investigator brochure where required, chemistry and manufacturing information, and nonclinical safety data.
- Review: the IND goes into effect 30 days after FDA receives it, unless FDA imposes a clinical hold, or earlier if FDA says the study may begin (21 CFR 312.40(b)).
- IND safety reports: serious and unexpected suspected adverse reactions go to FDA and all participating investigators within 15 calendar days of the sponsor determining that they qualify; unexpected fatal or life-threatening ones must also be reported to FDA within 7 calendar days of first receipt (21 CFR 312.32(c)).
- Annual report: within 60 days of the anniversary of the IND going into effect (21 CFR 312.33).
Devices: the IDE (21 CFR Part 812)
Significant-risk device studies need an FDA-approved IDE. Non-significant-risk studies follow abbreviated requirements, with IRB approval.
An example timeline
- Months 0 to 3: protocol development and pre-IND meeting.
- Month 4: IND or IDE submission.
- Month 5: FDA review period and IRB submission.
- Month 6: first participant, if there is no clinical hold.
Every study differs; use this only as a starting point.
Common pitfalls
- Insufficient nonclinical safety data for first-in-human studies.
- Incomplete chemistry, manufacturing and controls (CMC) documentation.
- Design gaps: endpoints, safety monitoring or statistical power.
- Consent forms missing required elements.
Checklist
IND submission checklist
- Pre-IND meeting considered
- Form FDA 1571 cover sheet
- Form FDA 1572 obtained from each investigator before they take part (21 CFR 312.53(c))
- Financial disclosure information from each investigator (21 CFR Part 54)
- Final protocol
- Investigator brochure, where required
- Chemistry, manufacturing and controls information
- Pharmacology and toxicology information
- Plans for IND safety reports (15 days, plus a 7-day report for unexpected fatal or life-threatening reactions) and the annual report (within 60 days of the anniversary)
- No enrollment until the IND is in effect and the IRB has approved
Practice with KLINiLEARN
Test yourself on this topic
- Module 2: Does your study need an IND?The Sponsor-Investigator, free practice course
- Module 3: Filing and keeping the INDThe Sponsor-Investigator, free practice course
- Module 4: Your sponsor dutiesThe Sponsor-Investigator, free practice course
- Module 2: Significant risk or non-significant risk?Device and Diagnostic Studies, free practice course
- Module 3: The IDE and sponsor dutiesDevice and Diagnostic Studies, free practice course
We support IND and IDE applications, FDA communications and ongoing compliance throughout the trial.
Sources
- 21 CFR Part 312: Investigational New Drug Application
- 21 CFR Part 812: Investigational Device Exemptions
- 21 CFR 312.32: IND safety reporting
- 21 CFR 312.33: Annual reports
- 21 CFR 312.82: Early consultation (pre-IND meetings)
- 21 CFR 312.23: IND content and format (Form FDA 1571)
- 21 CFR 312.40: When an IND goes into effect
- Form FDA 1572: Statement of Investigator
- 21 CFR 312.53: Selecting investigators and monitors
General guidance only. Always check the current regulations and your protocol.